Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference

Rhea-AI Summary

Heat Biologics (Nasdaq:HTBX) announced its participation in the 2021 BIO CEO & Investor Digital Conference from February 16-18, 2021. The company specializes in developing therapies to enhance the immune system, with a focus on oncology and COVID-19 vaccines. Attendees can access Heat's presentation on-demand starting February 16th for 30 days. After the conference, the presentation will be available on Heat Biologics' investor relations website.

Heat's pipeline includes clinical trials for products like HS-110 and a COVID-19 vaccine.

DURHAM, NC / ACCESSWIRE / February 12, 2021 / Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that it will be presenting at the 2021 BIO CEO & Investor Digital Conference being held virtually between February 16-18, 2021.

A webcast of Heat's presentation will be available on-demand to registered attendees beginning Tuesday, February 16^th, and will be accessible for 30 days via the conference platform. Subsequent to the conference, the presentation will be made available on the investor relations section of Heat Biologics' website at https://ir.heatbio.com/ir-calendar.

At the BIO CEO & Investor Digital Conference attendees will hear key biotech and pharma leaders discuss the most pertinent industry trends, the market outlook, and best practices for executive leadership. For more information about the BIO CEO & Investor Conference, please visit the conference website at https://www.bio.org/events/bio-ceo-investor-digital-conference.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/629550/Heat-Biologics-to-Present-at-2021-BIO-CEO-Investor-Digital-Conference

FAQ

What is Heat Biologics presenting at the BIO CEO & Investor Digital Conference?

Heat Biologics will present its innovative therapies aimed at modulating the immune system, including oncology products and a COVID-19 vaccine.

When is Heat Biologics' presentation at the conference?

Heat Biologics' presentation will be available on-demand starting February 16th, 2021, and accessible for 30 days.

Where can I find Heat Biologics' presentation after the conference?

The presentation will be available on Heat Biologics' investor relations section on their website after the conference.

What product candidates is Heat Biologics developing?

Heat Biologics is developing several product candidates, including HS-110, which is in Phase 2 trials, and a COVID-19 vaccine currently in preclinical development.

What is the focus of Heat Biologics' research?

Heat Biologics focuses on developing therapies that modulate the immune system for cancer treatment and infectious diseases.